Peking University People's Hospital — Clinical Trial Pipeline

Peking University People's Hospital has 8 registered trials in the index.

Trials (8)

• Treatment Duration of IPA N/A · Peking University People's Hospital
• ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer Phase 2 · Peking University People's Hospital
• Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment N/A · Peking University People's Hospital
• C-CAR011 Treatment in Subjects With ALL After HSCT N/A · Peking University People's Hospital
• Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia N/A · Peking University People's Hospital
• Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients N/A · Peking University People's Hospital
• CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT Phase 3 · Peking University People's Hospital
• Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma Phase 2 · Peking University People's Hospital

Related landscapes

• Invasive Aspergillosis
• Antifungal Therapy
• Hormone Receptor-Positive Breast Cancer
• High-risk Breast Cancer
• Early-Stage Breast Cancer

Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.